Kang Z, Liu Y, Xu L, Long Z, Huang D, Yang Y, et al. The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 2016;35:48.

Article  PubMed  PubMed Central  Google Scholar 

Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019;12:39.

Article  PubMed  PubMed Central  Google Scholar 

Luttman JH, Colemon A, Mayro B, Pendergast AM. Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade. Cell Commun Signal. 2021;19:59.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551–69.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoemberger M, Pitsawong W, Kern D. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proc Natl Acad Sci USA. 2020;117(32):19221–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pophali PA, Patnaik MM. The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 2016;22(1):40–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–406.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaitanya PK, Kumar KA, Stalin B, Sadashivudu G, Srinivas ML. The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: single-institutional experience over 13 years. Indian J Med Paediatr Oncol. 2017;38(3):328–33.

Article  PubMed  PubMed Central  Google Scholar 

Srivastava S, Dutt S. Imatinib mesylate resistance and mutations: an Indian experience. Indian J Med Paediatr Oncol. 2013;34(3):213–20.

Article  PubMed  PubMed Central  Google Scholar 

Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers (Basel). 2022;14(14):3300.

Article  CAS  PubMed  Google Scholar 

Chan O, Talati C, Isenalumhe L, Shams S, Nodzon L, Fradley M, et al. Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia. Blood Adv. 2020;4(3):530–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erçalışkan A, Seyhan Erdoğan D, Eşkazan AE. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Adv. 2021;5(17):3344–53.

Article  PubMed  PubMed Central  Google Scholar 

Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37(4):530–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:84.

Article  PubMed  PubMed Central  Google Scholar 

Yusoff YM, Seman ZA, Othman N, Kamaluddin NR, Esa E, Zulkiply NA, et al. Prevalence of BCR-ABL T315I mutation in Malaysian patients with imatinib-resistant chronic myeloid leukemia. Asian Pac J Cancer Prev. 2018;19(12):3317–20.

Article  CAS  PubMed Central  Google Scholar 

Larocque EA, Naganna N, Opoku-Temeng C, Lambrecht AM, Sintim HO. Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase. ChemMedChem. 2018;13(12):1172–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao Q, Wu ZE, Li B, Li F. Recent advances in metabolism and toxicity of tyrosine kinase inhibitors. Pharmacol Ther. 2022;237: 108256.

Article  CAS  PubMed  Google Scholar 

Baier A, Szyszka R. Compounds from natural sources as protein kinase inhibitors. Biomolecules (Basel, Switzerland). 2020;10(11):1546.

CAS  Google Scholar